Upadacitinib hemihydrate
Upadacitinib hemihydrate Basic information
- Product Name:
- Upadacitinib hemihydrate
- Synonyms:
-
- 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-
- Upadacitinib hemihydrate
- Upadacitinib Hydrate
- Cinchonanium, 1-[13,5-bis(trifluoromethyllphenyllmethyl]-9-hydroxy-1'- [[3-(trifluoromethyl)phenyllmethyl},bromide(1:2), (8a,9R)-"
- ABT 494 hemihydrate
- ABT494 hemihydrate
- ABT-494 hemihydrate
- CAS:
- 2050057-56-0
- MF:
- C17H21F3N6O2
- MW:
- 398.39
- Product Categories:
-
- API
- Mol File:
- 2050057-56-0.mol
More
Less
Upadacitinib hemihydrate Chemical Properties
- InChI
- InChI=1/C17H19F3N6O.H2O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15;/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27);1H2/t10-,11+;/s3
- InChIKey
- VJSRYIXHEWRBKD-NFGOAHBONA-N
- SMILES
- C([C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2C=NC3NC=CC=3N12)C.O |&1:1,13,r|
More
Less
Upadacitinib hemihydrate Usage And Synthesis
Clinical Use
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. Each prolonged-release tablet (RINVOQ 15 mg prolonged-release tablets.) contains upadacitinib hemihydrate, equivalent to 15 mg of upadacitinib.
Upadacitinib hemihydrateSupplier
HANGZHOU KELAI BIOMEDICAL TECHNOLOGY Co., Ltd. Gold
- Tel
- 18957050573
- 752803249@qq.com
Taizhou Yuxin Biotechnology Co., Ltd., Gold
- Tel
- +86-0576--88902229 +86-13968687450
- yuxin@yuxchem.com
Shandong Yuhe Pharmaceutical Technology Co., LTD Gold
- Tel
- 15263077727
- 1436425847@qq.com
Jiangxi Zhiyan Biopharmaceutical Technology Co., Ltd Gold
- Tel
- 13732973797
- liu@zybiopharma.com
Changzhou Borl Biotechnology Co.,LTD Gold
- Tel
- 13606124132;13656121842
- luyan0021@163.com